Details for Patent: 8,470,364

Which drugs does patent 8,470,364 protect, and when does it expire?

Patent 8,470,364 protects ORACEA and is included in one NDA.

This patent has eighteen patent family members in eight countries.

Summary for Patent: 8,470,364

Scope and claims summary:

Title:	Once daily formulations of tetracyclines
Abstract:	Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
Inventor(s):	Chang; Rong-Kun (Rockville, MD), Raoufinia; Arash (Springfield, VA), Shah; Niraj (Owings Mills, MD)
Assignee:	Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:	12/926,933
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,470,364
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form; Use;

Drugs Protected by US Patent 8,470,364

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	AB	RX	Yes	Yes			Y			TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

International Family Members for US Patent 8,470,364

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2521885
Canada	2803922
Canada	2894736
Denmark	1615622